Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury
24 oktober, 2025
24 oktober, 2025
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Mirtazapin Newbury 15, 30 and 45 mg tablets in Sweden.
Mirtazapin Newbury is a noradrenergic and specific serotonergic antidepressant indicated for the treatment of episodes of major depression in adults.
The current annual value of the Swedish market is estimated to be 5 MEUR according to DLMI Nordic Pharma Insights.
For more information, contact:
Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005
About Newbury Pharmaceuticals
Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.
Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.
Attachments
Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury
24 oktober, 2025
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Mirtazapin Newbury 15, 30 and 45 mg tablets in Sweden.
Mirtazapin Newbury is a noradrenergic and specific serotonergic antidepressant indicated for the treatment of episodes of major depression in adults.
The current annual value of the Swedish market is estimated to be 5 MEUR according to DLMI Nordic Pharma Insights.
For more information, contact:
Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005
About Newbury Pharmaceuticals
Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.
Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.
Attachments
Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury
Fonder
Analys
Bolåneräntorna
ETF:er
Fonder
Analys
Bolåneräntorna
ETF:er
1 DAG %
Senast
OMX Stockholm 30
2,63%
(vid stängning)
OMX Stockholm 30
1 DAG %
Senast
3 006,37